Home LiteratureArticle Details
PMID: 6174352 Published · ppublish English Journal Article

The effects of 5-hydroxytryptamine-depleting drugs on peptides in the ventral spinal cord.

European journal of pharmacology ·Vol. 76 ·No. 2-3 ·1981-12-03 ·Pages 203-10

Gilbert RF, Bennett GW, Marsden CA, Emson PC

Abstract

The ventral spinal cord content of several neuronally localised peptides was measured after treatment with a number of drugs which deplete spinal cord monoamines. Reserpine and tetrabenazine, but not p-chlorophenylalanine caused a partial depletion of ventral spinal cord substance P (SP) and thyrotropin-releasing hormone (TRH). Two other peptides, methionine-enkephalin and somatostatin were not depleted by any of the drugs. The rates of loss and recovery of SP and TRH after reserpine and tetrabenazine were different from that of 5-hydroxytryptamine (5-HT), though in the ventral spinal cord these two peptides probably coexist with 5-HT in the terminals of bulbospinal neurones. The results are discussed in relation to the possible costorage of SP and TRH with 5-HT in the same vesicles in nerve terminals in the ventral spinal cord.

MeSH Terms
Animals Male Rats Reserpine/pharmacology Serotonin/analysis,metabolism Spinal Cord/analysis,drug effects Substance P/analysis Tetrabenazine/pharmacology Thyrotropin-Releasing Hormone/analysis
Chemicals
Serotonin Substance P Thyrotropin-Releasing Hormone Reserpine Tetrabenazine
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Gilbert R F
Bennett G W
Marsden C A
Emson P C
Article Info
Journal
European journal of pharmacology
Abbr.
Eur J Pharmacol
ISSN
0014-2999
Published
1981-12-03
Pages
203-10
Language
English
Region
Netherlands
NLM ID
1254354
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com